A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis
NCT04875754 is a phase 1/2 interventional trial sponsored by ICM Biotech Australia Pty Ltd.. As of 21 Nov 2026, it is completed. It studies Placebo in Osteoarthritis, Knee. The registry lists an enrollment of 12 participants at 2 sites in 1 country. The registry lists a start date of 17 Mar 2022 and a primary completion date of 20 Feb 2026.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04875754 |
| Status | Completed |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | ICM Biotech Australia Pty Ltd. |
| Enrollment | 12 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Osteoarthritis, Knee |
| Drugs | Placebo |
| Start | 17 Mar 2022 |
| Primary completion | 20 Feb 2026 |
| Study completion | 20 Feb 2026 |
| Last update posted | 3 Sept 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Alison Heald, MD
ICM Co. Ltd.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal Adelaide Hospital
Adelaide, South Australia
- Barwon Health
Geelong, Victoria
Sites by country
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04875754
Each answer restates registry values shown on this page.
What is NCT04875754?
NCT04875754 is a phase 1/2 interventional trial sponsored by ICM Biotech Australia Pty Ltd.. It studies Placebo in Osteoarthritis, Knee.
Who leads NCT04875754?
The registry names Alison Heald, MD (study director, ICM Co. Ltd.) as the overall official.
Where does NCT04875754 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: Australia.
Which drugs does NCT04875754 study?
The registered drug and biological interventions are Placebo.
When did NCT04875754 end?
The registry lists a primary completion date of 20 Feb 2026 and a study completion date of 20 Feb 2026. The sponsor last updated the record on 3 Sept 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.